Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Q: How long will it take to read this news story?

The story "Mankind Pharma inks pact with Innovent for immunotherapy drug in India" has 345 words across 14 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Mankind Pharma inks pact with Innovent for immunotherapy drug in India" was covered 17 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 211 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #24673742</li><li>URL: https://beamstart.com/news/mankind-pharma-inks-pact-with-17352212938641</li></ul>

Business Standard Logo Business Standard 17h ago

Mankind Pharma inks pact with Innovent for immunotherapy drug in India - Business Standard

Quick Summary:

Early next year, we will be filing for its regulatory approval in India and complete all mandatory regulatory processes, including the conducting of a phase 3 clinical trial by Mankind Pharma for its successful approval in India once we receive the permission from the regulator to conduct such clinical trials," a Mankind Pharma spokesperson said.

Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market.

This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region, the companies said in a joint statement.